NewYork-Presbyterian/Columbia University Irving Medical Center, also known as the Columbia University Irving Medical Center, is an academic medical center and the largest campus of NewYork-Presbyterian Hospital.

During the past decade, New York Presbyterian Hospital conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 47 clinical trials were completed, i.e. on average, 94% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 18 clinical trials were completed. i.e. 105.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Presbyterian Hospital" #1 sponsor was "Columbia University" with 13 trials, followed by "Novartis Pharmaceuticals" with 7 trials sponsored, "Gilead Sciences" with 6 trials sponsored, "Boston Scientific Corporation" with 5 trials sponsored and "Bristol-Myers Squibb" with 5 trials sponsored. Other sponsors include 105 different institutions and companies that sponsored additional 80 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Presbyterian Hospital" #1 collaborator was "New York Presbyterian Hospital" with 7 trials as a collaborator, "Agency for Healthcare Research and Quality (AHRQ)" with 3 trials as a collaborator, "M.D. Anderson Cancer Center" with 2 trials as a collaborator, "National Institute of Mental Health (NIMH)" with 2 trials as a collaborator and "University of Wisconsin, Madison" with 2 trials as a collaborator. Other collaborators include 65 different institutions and companies that were collaborators in the rest 74 trials.

According to Clinical.Site data, the most researched conditions in "New York Presbyterian Hospital" are "Crohn's Disease" (6 trials), "Pulmonary Hypertension" (5 trials), "Coronary Artery Disease" (4 trials), "Multiple Myeloma" (4 trials) and "Postoperative Pain" (3 trials). Many other conditions were trialed in "New York Presbyterian Hospital" in a lesser frequency.

Most popular intervention types in "New York Presbyterian Hospital" are "Drug" (86 trials), "Device" (29 trials), "Behavioral" (12 trials), "Other" (12 trials) and "Biological" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "vedolizumab" (3 trials), "Control" (2 trials), "Dasatinib" (2 trials) and "Enoxaparin" (2 trials). Other intervention names were less common.

The vast majority of trials in "New York Presbyterian Hospital" are 134 trials for "All" genders, 9 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 25 active trials in "New York Presbyterian Hospital". 2 are not yet recruiting, 15 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 94 completed trials in New York Presbyterian Hospital, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in New York Presbyterian Hospital, 9 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 18 trials, and there were also 33 trials that are defined as “Not Applicable".